Skip to main content

39M euro invested in VUB spin-off eTheRNA to boost mRNA therapeutics

  • September 1, 2022
  • Alena aga

mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers invest in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA to expand its expertise and capabilities as a one-stop service to bring RNA-based research and products from the lab to the clinic.

Read the full article on VUB Today

Read the article in De Tijd